Authors : Ilangovan Subashree, Geetha Prasad
DOI : 10.18231/2394-2754.2018.0088
Volume : 5
Issue : 3
Year : 0
Page No : 384-388
Introduction: Uterine Fibroids are common growth of female reproductive tract in women of reproductive age group. So this prospective observational study was conducted to evaluate the effect of low dose Mifepristone treatment for 6 months on the outcome of fibroid size and related symptom.
Materials and Methods: The study was a prospective observational study conducted at Tertiary care Hospital, Tamil Nadu during the period of July 2016 to June 2017. Forty five patients with symptomatic fibroid, aged between 24-45 years were recruited for the study. Baseline data regarding fibroid volume, Hb value, PBAC (Pictorial Blood Assessment Chart) & VAS (Visual analogue Scheme) score were recorded. The follow-up data regarding above parameters again collected at the end of 6 months of therapy. All patients received 25mg mifepristone daily and comparison was made between pre and post treatment symptoms and leiomyoma volume.
Results: After therapy with Mifepristone there was a significant reduction in mean volume of fibroid, menorrhagia and pain related symptoms. The mean leiomyoma volume was reduced from 104.3mm3 to 56.8 mm3 by the end of 6 months of mifepristone therapy. Similarly, at the end of six months of therapy mean hemoglobin value was also raised by 2.8gm/dl from the baseline mean value of 7.9gm/dl. There were no major side effects observed during the course of the study and the drug was well tolerated.
Conclusion: Mifepristone is effective against low size uterine leiomyoma and can decrease its associated symptoms among women with symptomatic fibroids.
Keywords: Mifepristone, Leiomyoma, Clinical treatment, Menorrhagia, Dysmenorrhea, Uterine fibroid, Volume of fibroid, Leiomyoma.